Drugs / PF-06939999
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03854227 | Mar 2019 → Apr 2022 | cancer, metastatic neoplasm | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06939999 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03854227 ↗ |
| Action | Inhibit | “PF-06939999, a small-molecule inhibitor of protein arginine methyltransferase 5” PMID 36394153 ↗ Nov 2022 |
| Modality | Small molecule | “PF-06939999, a small-molecule inhibitor of protein arginine methyltransferase 5” PMID 36394153 ↗ Nov 2022 |
| Route | Oral | “PF-06939999 orally at escalating doses on a continuous basis” NCT03854227 ↗ |
| Target | PRMT5 | “PF-06939999, a small-molecule inhibitor of protein arginine methyltransferase 5” PMID 36394153 ↗ Nov 2022 |